DrugSupplement
Silybin clinical trials
Also written Silibinin.
Includes 1 study of Silybin-phytosome.
- studies test it
- 16
- open now
- 2
- in phase 3
- 2
- first study started
- 2007
Keep track of what changes. Save the Silybin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Other names
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 2
- Phase 4
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 12
University of Catania (2) · Rottapharm (2) · Universidad Católica San Antonio de Murcia (1) · Masonic Cancer Center, University of Minnesota (1) · University Magna Graecia (1) · Medical University of Vienna (1) · The University of Texas Health Science Center at San Antonio (1) · University of Malaya (1)
Often tested with
Tested in the same studies.
Indole-3-carbinol (1) · Acetylcysteine (1) · Silymarin (1) · Daunorubicin (1) · Idarubicin (1) · Erlotinib (1)
Studies
Open first, then newest update. How each study uses Silybin is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).RecruitingPhase 4Fujian Medical University Union HospitalNCT07561892Written as daunomycin/Idarubicin+ Silybinin
- SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)RecruitingNot applicableA.O.U. Città della Salute e della ScienzaNCT05689619Written as Silibinin
- Effect of Silibinin(A) as a Potential Anti-obesity AgentActive, not recruitingNot applicableUniversidad Católica San Antonio de MurciaNCT05069298Written as Silibinin A
- Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom PoisoningTerminatedPhase 2Mylan Specialty, LPNCT00915681Written as Silibinin
- Trial of Indole-3-Carbinol and SilibininCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT03687073Written as Silibinin
- Effects of Silybin in Hypertensive PatientsCompletedPhase 4University Magna GraeciaNCT03538327Written as Silybin
- Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in NonrespondersCompletedPhase 2Medical University of ViennaNCT00684268Written as Silibinin
- N-Acetylcysteine and Milk Thistle for Treatment of Diabetic NephropathyCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT00915200Written as silibin
- Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedPhase 2University of MalayaNCT02006498Written as Sillymarin
- THISTLE - The HIV-HCV Silibinin TrialCompletedPhase 2University of ZurichNCT01816490Written as Intravenous Silibinin (iSIL)
- Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted PatientsTerminatedPhase 2RottapharmNCT01518933Written as Silibinin (Legalon-SIL)
- A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaStatus unknownPhase 2MedicalLogicNCT02146118Written as Silybin-phytosome
- Siliphos in Advanced Hepatocellular CarcinomaCompletedPhase 1Abby SiegelNCT01129570Written as Silybin
- Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work AbilityCompletedPhase 3University of CataniaNCT01957319Written as Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg
- Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBVCompletedPhase 3University of CataniaNCT01935817Written as Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex
- Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted PatientsTerminatedPhase 2RottapharmNCT01535092Written as Silibinin
Given in every arm · 1 — Silybin is usual care beside what is tested
As the comparator · 2 — what is tested is compared with Silybin
- TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.Status unknownPhase 3Nhat Nhat Pharmaceutical CompanyNCT03216668Written as LEGALON
- To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver DiseaseCompletedPhase 4PharmaKingNCT02347319Written as Legalon
Codes
What other systems call Silybin · ClinicalTrials.gg INT006711
- MeSH (NLM) D000077385SilybinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 33X338MNE4SILIBININ AConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077385 | Silybin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 33X338MNE4 | SILIBININ A | Confirmed FDA, NLM |
Also registered as silibinin (UNII 4RKY41TBTF · RxNorm 155067) and silibinin b (UNII 853OHH1429).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.